Elisabeth Leiderman
CIK 1842133 · Chief Financial Officer · last filed 2025-06-03
Elisabeth Leiderman is a Chief Financial Officer who has filed 8 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for BLUE, was dated Jun 3, 2025. Across all open-market trades the lifetime net is −$6.5K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
8
-$6.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| bluebird bio, Inc. (BLUE) Delisted | Director | 0 | $4.97 | $0 | -$6.5K | 6 | 2025-06-03 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Chief Financial Officer | — | $4.91 | — | $0 | 1 | 2022-02-28 |
| bluebird bio, Inc. (BLUEV) Delisted | Director | 4,663 | — | — | $0 | 1 | 2021-10-19 |
Recent Filings
8 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-03 | bluebird bio, Inc. (BLUE) Delisted | Mixed | −2,357 | $0 | EDGAR |
| 2024-11-08 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | +24,900 | $0 | EDGAR |
| 2023-06-20 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | +10,790 | $0 | EDGAR |
| 2023-03-09 | bluebird bio, Inc. (BLUE) Delisted | Sell (S) | −1,004 | -$6.5K | EDGAR |
| 2022-06-23 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | +3,109 | $0 | EDGAR |
| 2022-02-28 | Decibel Therapeutics, Inc. (DBTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-16 | bluebird bio, Inc. (BLUE) Delisted | Mixed | +9,361 | $0 | EDGAR |
| 2021-10-19 | bluebird bio, Inc. (BLUEV) Delisted | Grant (A) | +4,663 | $0 | EDGAR |